Gilead Sciences (GILD) Financials: History & Chart

Gilead Sciences, Inc. (GILD)GILDGilead Sciences, Inc.

About Gilead Sciences, Inc.

Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.

Foster City, CA

17,000 employees

www.gilead.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Daniel O'Day

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024	Quarter ended Jun 2024
Revenue	29.73B	6.96B	7.92B	7.77B	7.08B	6.67B	7.57B	7.54B	6.95B
Cost of Goods Sold	6.14B	1.45B	1.62B	1.57B	1.50B	1.54B	1.58B	1.57B	1.54B
Gross Profit	23.59B	5.51B	6.30B	6.20B	5.58B	5.13B	5.99B	5.97B	5.41B
Gross Profit Margin	79.4%	79.2%	79.5%	79.8%	78.8%	76.9%	79.1%	79.1%	77.8%
Total Operating Expenses	12.22B	2.93B	3.31B	2.87B	3.11B	2.89B	3.54B	5.08B	2.77B
Research & Development	5.79B	1.37B	1.58B	1.35B	1.49B	1.38B	1.64B	1.40B	1.35B
Selling, General & Administrative	5.90B	1.45B	1.73B	1.36B	1.36B	1.26B	1.86B	1.41B	1.38B
Operating Income (EBIT)	11.38B	2.59B	2.99B	3.33B	2.47B	2.24B	2.45B	888.00M	2.64B
Operating Margin	38.3%	37.2%	37.7%	42.8%	34.9%	33.6%	32.4%	11.8%	38.0%
Income Before Tax (EBT)	10.73B	2.58B	2.08B	3.64B	2.43B	1.65B	2.17B	956.00M	2.05B
Interest Income	256.00M	N/A	95.00M	88.00M	73.00M	94.00M	85.00M	52.00M	35.00M
Interest Expense	1.00B	240.00M	255.00M	256.00M	254.00M	260.00M	249.00M	238.00M	237.00M
Other Income/Expense	-647.00M	-6.00M	-910.00M	314.00M	-45.00M	-588.00M	-285.00M	68.00M	-591.00M
Net Income	9.22B	2.02B	2.18B	3.05B	1.96B	1.31B	1.78B	1.25B	1.61B
Income Tax Expense	1.51B	559.00M	-105.00M	589.00M	468.00M	334.00M	385.00M	-297.00M	438.00M
Net Profit Margin	31.0%	29.0%	27.5%	39.3%	27.7%	19.7%	23.6%	16.6%	23.2%
EBITDA	14.13B	3.27B	3.67B	4.01B	3.17B	2.93B	3.15B	1.58B	3.34B
EBITDA Margin	47.5%	47.1%	46.4%	51.7%	44.7%	44.0%	41.6%	20.9%	48.0%
Depreciation & Amortization	2.75B	689.00M	687.00M	686.00M	691.00M	696.00M	693.00M	690.00M	694.00M
EPS Basic	7.42	1.63	1.76	2.46	1.57	1.06	1.43	1.00	1.29
EPS Diluted	7.34	1.61	1.74	2.43	1.56	1.04	1.42	1.00	1.29
Shares Outstanding	1.24B	1.24B	1.24B	1.24B	1.25B	1.25B	1.25B	1.25B	1.25B
Diluted Shares Outstanding	1.25B	1.25B	1.25B	1.25B	1.25B	1.26B	1.26B	1.25B	1.25B

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	29.44B	28.75B	27.12B	27.28B	27.30B	24.69B	22.45B	22.13B
Cost of Goods Sold	6.23B	6.25B	6.50B	5.66B	6.60B	4.57B	4.67B	4.85B
Gross Profit	23.21B	22.50B	20.62B	21.62B	20.70B	20.12B	17.77B	17.27B
Gross Profit Margin	78.8%	78.3%	76.0%	79.3%	75.8%	81.5%	79.2%	78.1%
Total Operating Expenses	11.51B	20.84B	13.01B	14.29B	10.79B	16.05B	8.44B	7.98B
Research & Development	5.80B	5.91B	5.72B	4.98B	4.60B	5.04B	4.05B	3.92B
Selling, General & Administrative	5.71B	6.09B	6.09B	5.67B	5.25B	5.11B	4.38B	4.06B
Operating Income (EBIT)	11.70B	1.66B	7.61B	7.33B	9.92B	4.07B	4.29B	8.20B
Operating Margin	39.7%	5.8%	28.0%	26.9%	36.3%	16.5%	19.1%	37.1%
Income Before Tax (EBT)	9.80B	690.00M	6.86B	5.81B	8.28B	1.67B	5.16B	7.80B
Interest Income	349.00M	281.00M	376.00M	106.00M	N/A	N/A	N/A	N/A
Interest Expense	1.02B	977.00M	944.00M	935.00M	1.00B	984.00M	995.00M	1.08B
Other Income/Expense	-1.91B	-972.00M	-746.00M	-1.52B	-1.64B	-2.40B	873.00M	-401.00M
Net Income	8.51B	480.00M	5.67B	4.59B	6.22B	123.00M	5.39B	5.46B
Income Tax Expense	1.29B	211.00M	1.25B	1.25B	2.08B	1.58B	-204.00M	2.34B
Net Profit Margin	28.9%	1.7%	20.9%	16.8%	22.8%	0.5%	24.0%	24.7%
EBITDA	14.46B	4.43B	10.30B	9.43B	11.97B	5.55B	5.69B	9.63B
EBITDA Margin	49.1%	15.4%	38.0%	34.6%	43.8%	22.5%	25.4%	43.5%
Depreciation & Amortization	2.76B	2.77B	2.69B	2.10B	2.05B	1.48B	1.40B	1.43B
EPS Basic	6.84	0.38	4.54	3.66	4.96	0.10	4.24	4.20
EPS Diluted	6.78	0.38	4.50	3.64	4.93	0.10	4.22	4.17
Shares Outstanding	1.24B	1.25B	1.25B	1.25B	1.26B	1.26B	1.27B	1.30B
Diluted Shares Outstanding	1.25B	1.25B	1.26B	1.26B	1.26B	1.26B	1.28B	1.31B

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.